Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson’s disease

H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) today announced signing of a definitive agreement in which Lundbeck will acquire Prexton.

OxThera announces the randomization of the first patient into its phase III EPHEX study with Oxabact

OxThera AB, announces the randomization of the first patient into its phase III study, EPHEX, with Oxabact.

AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury

AM‐Pharma B.V., today announced positive results from its adaptive Phase II study in 301 sepsis patients with Acute Kidney Injury (AKI), the largest therapeutic study in AKI to date.

Sanifit Announces Results of the Phase II Clinical Trial of SNF472 in Patients with Calciphylaxis

Laboratoris Sanifit S.L., announced today the completion of its Phase II clinical trial of SNF472, its lead candidate for the treatment of the orphan disease calciphylaxis, with both primary and secondary endpoints being successfully met.

Kala Pharmaceuticals Appoints Gregory Perry to Board of Directors and as Audit Committee Chair

Kala Pharmaceuticals, Inc. today announced the appointment of Gregory Perry to the Company’s Board of Directors and Chair of its Audit Committee.

Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain Therapeutics

Minoryx Therapeutics and Gain Therapeutics announce today the spin off of the Minoryx Site-directed Enzyme Enhancement Therapy (SEE-Tx) platform into Gain Therapeutics.

QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing

QIAGEN has agreed to acquire all shares of STAT-Dx for approximately $147 million in cash and additional payments of up to about $44 million.

BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer

BioClin Therapeutics, Inc.(BioClin), announced today the appointments of Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer.

Sanifit announces the appointment of Cris Calsada as Chief Financial Officer

Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the appointment of Cris Calsada as Chief Financial Officer.

STAT-Dx announces CE-IVD mark completion for DiagCORE® System and Respiratory Panel